These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 26966386)

  • 1. The cost-utility of treating anemia with continuous erythropoietin receptor activator or Epoetin versus routine blood transfusions among chronic hemodialysis patients.
    Maoujoud O; Ahid S; Cherrah Y
    Int J Nephrol Renovasc Dis; 2016; 9():35-43. PubMed ID: 26966386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Cost-Effectiveness of Continuous Erythropoiesis Receptor Activator Once Monthly versus Epoetin Thrice Weekly for Anaemia Management in Chronic Haemodialysis Patients.
    Maoujoud O; Ahid S; Dkhissi H; Oualim Z; Cherrah Y
    Anemia; 2015; 2015():189404. PubMed ID: 26843983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease.
    Saglimbene VM; Palmer SC; Ruospo M; Natale P; Craig JC; Strippoli GF
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD009904. PubMed ID: 28782299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment.
    Wilson J; Yao GL; Raftery J; Bohlius J; Brunskill S; Sandercock J; Bayliss S; Moss P; Stanworth S; Hyde C
    Health Technol Assess; 2007 Apr; 11(13):1-202, iii-iv. PubMed ID: 17408534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correction of anemia with continuous erythropoietin receptor activator in Korean patients on long-term hemodialysis.
    Oh J; Joo KW; Chin HJ; Chae DW; Kim SG; Kim SJ; Chung W; Kim S; Huh W; Oh HY; Choi BS; Yang CW; Kim S
    J Korean Med Sci; 2014 Jan; 29(1):76-83. PubMed ID: 24431909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time spent on erythropoietin stimulating agents administration in hemodialysis centers in Panama: a time and motion study.
    Chacón-Araya M; Rey-Rodríguez D; Rodríguez De León F; Ramos-Esquivel A; Sunning T
    J Med Econ; 2019 Aug; 22(8):736-741. PubMed ID: 30915883
    [No Abstract]   [Full Text] [Related]  

  • 7. Historical clinical and economic consequences of anemia management in patients with end-stage renal disease on dialysis using erythropoietin stimulating agents versus routine blood transfusions: a retrospective cost-effectiveness analysis.
    Naci H; de Lissovoy G; Hollenbeak C; Custer B; Hofmann A; McClellan W; Gitlin M
    J Med Econ; 2012; 15(2):293-304. PubMed ID: 22115328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hemoglobin maintenance and dosing strategies using intravenous continuous erythropoietin receptor activator in Japanese hemodialysis patients.
    Hirai T; Nishizawa Y; Nakazono H; Asai M; Yamashita H; Sasaki A; Yamashita T; Yamashita K; Shigemoto K; Harada S; Mizuiri S
    Ther Apher Dial; 2013 Oct; 17(5):498-503. PubMed ID: 24107278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term maintenance of hemoglobin levels in hemodialysis patients treated with bi-weekly epoetin beta pegol switched from darbepoetin alfa: a single-center, 12-month observational study in Japan.
    Kawai T; Kusano Y; Yamada K; Ueda C; Kawai A; Masaki T
    J Artif Organs; 2019 Jun; 22(2):146-153. PubMed ID: 30426250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Opatija study: observation of hemodialysis patients and titration of CERA dose just switched from another erythropoiesis stimulating agent].
    Jelić I; Lovcić V; Kurtović I; Josipović M; Havranek Z; Kostić L; Racki S
    Acta Med Croatica; 2012 Jul; 66(3):157-64. PubMed ID: 23441529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose equivalence between continuous erythropoietin receptor activator (CERA), Darbepoetin and Epoetin in patients with advanced chronic kidney disease.
    Vega A; Abad S; Verdalles U; Aragoncillo I; Velazquez K; Quiroga B; Escudero V; López-Gómez JM
    Hippokratia; 2014; 18(4):315-8. PubMed ID: 26052197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-utility analysis of survival with epoetin-alfa versus placebo in stage IV breast cancer.
    Martin SC; Gagnon DD; Zhang L; Bokemeyer C; Van Marwijk Kooy M; van Hout B
    Pharmacoeconomics; 2003; 21(16):1153-69. PubMed ID: 14594437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cost-effectiveness of treatment with erythropoietin compared to red blood cell transfusions for patients with chemotherapy induced anaemia: a Markov model.
    Borg S; Glenngård AH; Osterborg A; Persson U
    Acta Oncol; 2008; 47(6):1009-17. PubMed ID: 18770060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of continuous erythropoietin receptor activator in anemia.
    Schmid H
    Clinicoecon Outcomes Res; 2014; 6():319-30. PubMed ID: 25050070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Twice-monthly administration of a lower dose of epoetin beta pegol can maintain adequate hemoglobin levels in hemodialysis patients.
    Morikami Y; Fujimori A; Okada S; Kumei M; Mizobuchi N; Sakai M
    Ther Apher Dial; 2015 Apr; 19(2):138-43. PubMed ID: 25402974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of pain and efficacy of darbepoetin alfa and epoetin Beta pegol treatment in patients receiving peritoneal dialysis.
    Otsuka T; Sakai Y; Yui S; Sukegawa M; Suzuki A; Mugishima K; Sumi Y; Otsuka Y; Tsuruoka S
    J Nippon Med Sch; 2015; 82(1):21-6. PubMed ID: 25797871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microdiscectomy Is More Cost-effective Than a 6-Month Nonsurgical Care Regimen for Chronic Radiculopathy.
    Glennie RA; Urquhart JC; Koto P; Rasoulinejad P; Taylor D; Sequeira K; Miller T; Watson J; Rosedale R; Bailey SI; Gurr KR; Siddiqi F; Bailey CS
    Clin Orthop Relat Res; 2022 Mar; 480(3):574-584. PubMed ID: 34597280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuous erythropoietin receptor activator (Mircera) for renal anemia.
    McGahan L
    Issues Emerg Health Technol; 2008 Feb; (113):1-6. PubMed ID: 18354858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An economic evaluation of erythropoiesis-stimulating agents in CKD.
    Clement FM; Klarenbach S; Tonelli M; Wiebe N; Hemmelgarn B; Manns BJ
    Am J Kidney Dis; 2010 Dec; 56(6):1050-61. PubMed ID: 20932621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.